For this purpose, we used MDA-MB-231 cells, the most commonly used triple-negative breast cancer cell line model, which carry mutations in Ras effector pathway (BRAF and NF1 mutations). The gene discussed is BRAF; the disease is triple-negative breast carcinoma.